All Stories

  1. Non-invasive mPAP/VO2 slope as predictor of pulmonary exercise hemodynamics and outcome
  2. How It Really Happened‐the Development of Inhaled Iloprost for Pulmonary Arterial Hypertension
  3. IDO‐1 Promotes Pulmonary Vascular Remodeling Via Kynurenine Pathway in Pulmonary Arterial Hypertension
  4. Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis
  5. Detection of structural pulmonary changes with real-time high-fidelity analysis of expiratory CO2
  6. Soluble Transferrin Receptor-1 in Pulmonary Hypertension Associated with COPD
  7. Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta‐Registry
  8. Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease
  9. Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension
  10. Pulmonary Vascular Disease and Pulmonary Exercise Hemodynamics in Patients With Sjögren's Syndrome – A Cross-Sectional Study
  11. Pathogenic SMAD6 variants in patients with idiopathic and complex congenital heart disease associated pulmonary arterial hypertension
  12. Prognostic Relevance of Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Arterial Pressure Ratio and Its Association With Exercise Hemodynamics in Patients With Normal or Mildly Elevated Resting Pulmonary Arterial Pressure
  13. Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institute GoDeep Meta-Registry
  14. Prognostic relevance of Exercise Pulmonary Hypertension: Results of the multi-center PEX-NET Clinical Research Collaboration
  15. Reply to: The limits of normal of pulmonary arterial wedge pressure
  16. Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH‐CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative—group 3 pulmonary hypertension
  17. Association of PH-Targeted Therapy and Survival in Precapillary PH with mPAP between 21 and 24 mmHg
  18. Clinical Response to Pulmonary Arterial Hypertension Treatment Does Not Depend on Pulmonary Arterial Wedge Pressure: A Meta-Analysis Using Individual Participant Data from Randomized Clinical Trials
  19. Lung Fibrosis Is Linked to Increased Endothelial Cell Activation and Dysfunctional Vascular Barrier Integrity
  20. Severe pulmonary hypertension in chronic obstructive pulmonary disease – From clinical perspective to histological evidence
  21. Risk stratification and treatment goals in pulmonary arterial hypertension
  22. Pulmonary arterial wedge pressure in healthy subjects: a meta-analysis
  23. The prognostic relevance of exercise pulmonary hypertension in cardiac and pulmonary diseases
  24. Expiratory Venous Volume and Arterial Tortuosity are Associated with Disease Severity and Mortality Risk in Patients with COPD: Results from COSYCONET
  25. Compartment-specific remodeling patterns in end-stage chronic obstructive pulmonary disease with and without severe pulmonary hypertension
  26. The TREK‐1 potassium channel is a potential pharmacological target for vasorelaxation in pulmonary hypertension
  27. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era
  28. CT-derived lung vessel morphology correlates with prognostic markers in precapillary pulmonary hypertension
  29. Long-term sildenafil therapy for pulmonary veno-occlusive disease in association with melphalan therapy for multiple myeloma: A case report
  30. Myocardial strain parameters in pulmonary hypertension are determined by changes in volumetric function rather than by hemodynamic alterations
  31. Pulmonal veno-okklusive Erkrankung (PVOD)
  32. Pulmonale Hypertonie
  33. Let’s Talk About Respiratory Swings!
  34. Physical Activity, Depression and Quality of Life in COPD – Results from the CLARA II Study
  35. Pentastatin, a matrikine of the collagen IVα5, is a novel endogenous mediator of pulmonary endothelial dysfunction
  36. Die neue Definition und Klassifikation der pulmonalen Hypertonie
  37. Basement membrane product, endostatin, as a link between inflammation, coagulation and vascular permeability in COVID-19 and non-COVID-19 acute respiratory distress syndrome
  38. Hypoxia-inducible factor-2 may define different scenarios of COPD development/progression
  39. Apelin-17 to diagnose idiopathic pulmonary arterial hypertension: A biomarker study
  40. Abnormal pulmonary hemodynamics during exercise is associated with exercise capacity in COPD
  41. Prognostic Value of Exercise as Compared to Resting Pulmonary Hemodynamics in Patients with Normal or Mildly Elevated Pulmonary Arterial Pressure
  42. Updated definition of exercise pulmonary hypertension
  43. Single-cell transcriptomics reveals skewed cellular communication and phenotypic shift in pulmonary artery remodeling
  44. Impairment of the NKT–STAT1–CXCL9 Axis Contributes to Vessel Fibrosis in Pulmonary Hypertension Caused by Lung Fibrosis
  45. Pulmonary vascular disease and exercise hemodynamics in chronic liver disease
  46. Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis
  47. Left atrial acceleration factor as a magnetic resonance 4D flow measure of mean pulmonary artery wedge pressure in pulmonary hypertension
  48. Circulating microRNAs as molecular biomarkers for lung adenocarcinoma
  49. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension
  50. Severe Pulmonary Hypertension in COPD
  51. Lung vascular changes as biomarkers of severity in systemic sclerosis–associated interstitial lung disease
  52. Automated vortical blood flow-based estimation of mean pulmonary arterial pressure from 4D flow MRI
  53. Potassium Channels in the Transition from Fetal to the Neonatal Pulmonary Circulation
  54. Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022)
  55. Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease
  56. Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review
  57. Impairment of Inspiratory Muscle Function after COVID-19
  58. Revisiting the Large-Conductance Calcium-Activated Potassium (BKCa) Channels in the Pulmonary Circulation
  59. PCK2 opposes mitochondrial respiration and maintains the redox balance in starved lung cancer cells
  60. Monocytes and Macrophages Serve as Potent Prostaglandin D2 Sources during Acute, Non-Allergic Pulmonary Inflammation
  61. Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer
  62. The definition of pulmonary hypertension: history, practical implications and current controversies
  63. RGS5 Determines Neutrophil Migration in the Acute Inflammatory Phase of Bleomycin-Induced Lung Injury
  64. Low oxygen levels decrease adaptive immune responses and ameliorate experimental asthma in mice
  65. Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances
  66. Elevated pulmonary vascular resistance predicts mortality in COPD patients
  67. Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD
  68. Between inflammation and thrombosis: endothelial cells in COVID-19
  69. Chronisch-obstruktive Lungenerkrankung 2021 – die richtige Therapie für den richtigen Patienten
  70. Impact of Smoking Behavior on Survival Following Allogeneic Hematopoietic Stem Cell Transplantation – Smoking Cessation Matters
  71. Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways
  72. The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease
  73. Exercise Pulmonary Resistances Predict Long-Term Survival in Systemic Sclerosis
  74. Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension
  75. Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series
  76. Phospholipid dynamics in ex vivo lung cancer and normal lung explants
  77. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial
  78. Covid‑19 – was wir sicher wissen
  79. Clinical-Pathological Conference Series from the Medical University of Graz
  80. MR 4D flow-based mean pulmonary arterial pressure tracking in pulmonary hypertension
  81. TMEM16A Potentiation: Possible Drawbacks
  82. Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer
  83. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study
  84. Masterplan 2025 der Österreichischen Gesellschaft für Pneumologie (ÖGP) – die erwartete Entwicklung und Versorgung respiratorischer Erkrankungen in Österreich
  85. Endothelial Dysfunction Following Enhanced TMEM16A Activity in Human Pulmonary Arteries
  86. C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study
  87. CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis
  88. Basement Membrane Remodeling Controls Endothelial Function in Idiopathic Pulmonary Arterial Hypertension
  89. Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria – Results from the CLARA Project
  90. Multi-channel lung sound classification with convolutional recurrent neural networks
  91. Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020)
  92. No indication of insulin resistance in idiopathic pulmonary arterial hypertension with preserved physical activity
  93. Pulmonary hypertension in chronic obstructive pulmonary disease
  94. Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension
  95. Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue
  96. MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2
  97. Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations
  98. Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis
  99. Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease
  100. Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?
  101. Debating the new haemodynamic definition of pulmonary hypertension: much ado about nothing?
  102. Gluconeogenesis in cancer cells – Repurposing of a starvation-induced metabolic pathway?
  103. Take your drug and climb Machu Picchu!
  104. IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis
  105. Pulmonary and cardiac drugs: clinically relevant interactions
  106. Hämodynamische Definition der pulmonalen Hypertonie: Kommentar zu der vorgeschlagenen Änderung durch das 6th World Symposium on Pulmonary Hypertension
  107. Advanced interstitial lung fibrosis with emphysema and pulmonary hypertension with no evidence for interstitial lung disease on high resolution CT
  108. Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI)
  109. Disconnect between Fibrotic Response and Right Ventricular Dysfunction
  110. Potential role of exercise echocardiography and right heart catheterization in the detection of early pulmonary vascular disease in patients with systemic sclerosis
  111. Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic PAH
  112. The pulmonary haemodynamics during exercise – research network (PEX-NET) ERS Clinical Research Collaboration: investigating the prognostic relevance of exercise haemodynamics
  113. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis
  114. Quantitative CT‐derived vessel metrics in idiopathic pulmonary fibrosis: A structure–function study
  115. Long non‐coding RNAs influence the transcriptome in pulmonary arterial hypertension: the role of PAXIP1‐AS1
  116. Pulmonary hypertension in chronic lung disease and hypoxia
  117. Whole-Body Lung Function Test–Derived Outcome Predictors in Allogenic Stem Cell Transplantation
  118. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension
  119. Imatinib for right heart failure in COPD
  120. Cologne consensus conference on pulmonary hypertension – Update 2018
  121. Should patients with pulmonary hypertension fly and climb?
  122. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?
  123. Are anticoagulants still indicated in pulmonary arterial hypertension?
  124. Clinical-Pathological Conference Series from the Medical University of Graz
  125. Pulmonary hypertension in hypersensitivity pneumonitis.
  126. Right ventricular tissue doppler echocardiography in pulmonary hypertension
  127. Advancing into the details of pulmonary haemodynamics during exercise
  128. Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis
  129. Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions
  130. Crackle and Breathing Phase Detection in Lung Sounds with Deep Bidirectional Gated Recurrent Neural Networks
  131. Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach
  132. The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells
  133. Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension
  134. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension
  135. Healthy Lung Vessel Morphology Derived From Thoracic Computed Tomography
  136. Resident cell lineages are preserved in pulmonary vascular remodeling
  137. Pulmonary capillary recruitment in exercise and pulmonary hypertension
  138. Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality
  139. Network Analysis to Risk Stratify Patients With Exercise IntoleranceNovelty and Significance
  140. The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension
  141. No erythropoietin-induced growth is observed in non-small cell lung cancer cells
  142. MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas
  143. An official European Respiratory Society statement: pulmonary haemodynamics during exercise
  144. Importance of kynurenine in pulmonary hypertension
  145. Understanding exercise hemodynamics
  146. TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1α
  147. Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study
  148. Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox
  149. The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension
  150. Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to Hypoxia
  151. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis
  152. Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension
  153. Automated integer programming based separation of arteries and veins from thoracic CT images
  154. ESC-Leitlinie 2015: Diagnostik und Therapie der pulmonalen Hypertonie
  155. Pulmonale Hypertonie: Kölner Konsensus-Konferenz 2016
  156. Pulmonale Hypertonie bei Lungenkrankheiten: Empfehlungen der Kölner Konsensus-Konferenz 2016
  157. Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different?
  158. Why We Should Care about the Mysteries of Pulmonary Hypertension
  159. Does exercise pulmonary hypertension exist?
  160. Docosahexaenoic acid causes rapid pulmonary arterial relaxationviaKCa channel-mediated hyperpolarisation in pulmonary hypertension
  161. Counter-clockwise vortical blood flow in the main pulmonary artery in a patient with patent ductus arteriosus with pulmonary arterial hypertension: a cardiac magnetic resonance imaging case report
  162. Amitriptyline and carbamazepine utilize voltage-gated ion channel suppression to impair excitability of sensory dorsal horn neurons in thin tissue slice: An in vitro study
  163. Functional and molecular factors associated with TAPSE in hypoxic pulmonary hypertension
  164. TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers
  165. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial
  166. Forschung in Österreich – das Ludwig Boltzmann Institut für Lungengefäßforschung
  167. Survival in patients with borderline pulmonary arterial pressure
  168. Prognostic relevance of differential blood count in pulmonary arterial hypertension
  169. Native myocardial T1 mapping in pulmonary hypertension: correlations with cardiac function and hemodynamics
  170. Circulating endothelial progenitor cells are associated with PAH but they are heterogeneous
  171. Pulmonary arterial pressure in patients with myelodysplastic syndromes
  172. Pulmonal (arterielle) Hypertonie
  173. Pulmonalembolie und direkte orale Antikoagulantien
  174. Letter by Olschewski et al Regarding Article, “Upregulation of K 2P 3.1 K + Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation”
  175. Proposed new definition of exercise pulmonary hypertension decreases false-positive cases
  176. Pulmonale Hypertonie
  177. Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension – Insights From the IBUKI and AIR Studies –
  178. Selexipag for the Treatment of Pulmonary Arterial Hypertension
  179. Clinical Manifestations of Respiratory Bronchiolitis as an Incidental Finding in Surgical Lung Biopsies: A Retrospective Analysis of a Large Austrian Registry
  180. ESC-Leitlinien 2015 zur pulmonalen Hypertonie
  181. Sleep Related Breathing Disorders and Inflammation — The Missing Link? A Cohort Study Evaluating the Interaction of Inflammation and Sleep Related Breathing Disorders and Effects of Treatment
  182. Cardiopulmonary comorbidities are associated with hemodynamics in pulmonary arterial hypertension
  183. The influence of erythropoietin on growth and survival in non-small cell lung cancer cell lines
  184. Pressure Overload Creates Right Ventricular Diastolic Dysfunction in a Mouse Model: Assessment by Echocardiography
  185. Borderline pulmonary pressures in scleroderma - a ‘pre-pulmonary arterial hypertension’ condition?
  186. Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients
  187. Impact of cardiopulmonary comorbidities on pulmonary hemodynamics
  188. Blood Flow Vortices along the Main Pulmonary Artery Measured with MR Imaging for Diagnosis of Pulmonary Hypertension
  189. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization
  190. Imatinib for Pulmonary Arterial Hypertension - Wonder Drug or Killer Drug?
  191. Allgemeine Therapie der pulmonal arteriellen Hypertonie
  192. Einsatz von Imatinib bei Patienten mit Pulmonal Arterieller Hypertonie
  193. Moderne bildgebende Verfahren im Management der pulmonalen Hypertonie
  194. Gezielte Therapie der pulmonal arteriellen Hypertonie (PAH)
  195. Ion channels and transporters as therapeutic targets in the pulmonary circulation
  196. Characterization of Patients With Borderline Pulmonary Arterial Pressure
  197. Reply: Reading of Pulmonary Artery Pressure Tracings: The Best Compromise of Accuracy and Clinical Pertinence
  198. Diagnostik der pulmonalen Hypertonie – Neues nach dem 5. Weltkongress
  199. Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics
  200. Gluconeogenesis in cancer: Door wide open
  201. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients
  202. Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries
  203. Distinct Differences in Gene Expression Patterns in Pulmonary Arteries of Patients with Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis with Pulmonary Hypertension
  204. READING PULMONARY VASCULAR PRESSURE TRACINGS How to handle the problems of zero leveling and respiratory swings
  205. Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy
  206. Kurzatmiger Patient — nicht immer ist er nur untrainiert
  207. PCK2 activation mediates an adaptive response to glucose depletion in lung cancer
  208. Meprinβ, a novel mediator of vascular remodelling underlying pulmonary hypertension
  209. Quantification of Tortuosity and Fractal Dimension of the Lung Vessels in Pulmonary Hypertension Patients
  210. Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model – role of tumor stroma cells
  211. Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension–Targeted Therapy
  212. Evaluation of Elevated Mean Pulmonary Arterial Pressure Based on Magnetic Resonance 4D Velocity Mapping: Comparison of Visualization Techniques
  213. Was ist pulmonale Hypertonie?
  214. Non-invasive determination of pulmonary hypertension with dynamic contrast-enhanced computed tomography: a pilot study
  215. Updated Clinical Classification of Pulmonary Hypertension
  216. Pulmonary arterial hypertension
  217. Assessment and Prognostic Relevance of Right Ventricular Contractile Reserve in Patients With Severe Pulmonary Hypertension
  218. Docosahexaenoic acid (DHA)-induced heme oxygenase-1 attenuates cytotoxic effects of DHA in vascular smooth muscle cells
  219. PL-7 Positive Antisynthetase Syndrome and Pulmonary Hypertension
  220. Determination of cardiac output with dynamic contrast-enhanced computed tomography
  221. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
  222. Riociguat for the Treatment of Pulmonary Arterial Hypertension
  223. Pulmonary Hypertension
  224. Biomarkers in Pulmonary Hypertension
  225. A 57-Year-Old Woman With Obesity, Respiratory Insufficiency, and Slowed Mental State
  226. Die frühe Diagnose und Therapie der pulmonalen Hypertonie - Aspekte einer Vision
  227. Zero reference level for right heart catheterisation
  228. Double-Stranded RNA Attenuates the Barrier Function of Human Pulmonary Artery Endothelial Cells
  229. Stellungnahme der Österreichischen Röntgengesellschaft und der Österreichischen Gesellschaft für Pneumologie
  230. Loss of ABCG2 leads to right ventricular diastolic dysfunction in pulmonary hypertension
  231. Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension
  232. Prostacyclins
  233. Prostacyclins
  234. Exercise in Pulmonary Hypertension
  235. HbA1c in pulmonary arterial hypertension: A marker of prognostic relevance?
  236. Pulmonale Hypertonie
  237. Angiostatic Factors in the Pulmonary Endarterectomy Material from Chronic Thromboembolic Pulmonary Hypertension Patients Cause Endothelial Dysfunction
  238. Docosahexaenoic acid-induced unfolded protein response, cell cycle arrest, and apoptosis in vascular smooth muscle cells are triggered by Ca2+-dependent induction of oxidative stress
  239. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries
  240. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure
  241. Peroxisome Proliferator–Activated Receptor–β/δ, the Acute Signaling Factor in Prostacyclin-Induced Pulmonary Vasodilation
  242. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension
  243. Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011
  244. Rechtsherzkatheter-Untersuchung bei pulmonaler Hypertonie
  245. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations
  246. Regulation der Kaliumkanäle in humanen pulmonal-arteriellen glatten Muskelzellen
  247. Pulmonary vascular resistances during exercise in normal subjects: a systematic review
  248. Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells
  249. Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients
  250. Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension
  251. Prostacyclin and Prostaglandins
  252. Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy
  253. Therapie der pulmonal arteriellen Hypertonie (PAH)
  254. Assessment of Pulmonary Arterial Pressure During Exercise in Collagen Vascular Disease
  255. Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension
  256. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension
  257. Intimal Sarcoma of the Pulmonary Valve
  258. Portopulmonary hypertension: short review
  259. The effect of terbutaline on the absorption of pulmonary administered insulin in subjects with asthma
  260. Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma
  261. Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
  262. Noninvasive detection of early pulmonary vascular dysfunction in scleroderma
  263. Endothelin-1 Inhibits Background Two-Pore Domain Channel TASK-1 in Primary Human Pulmonary Artery Smooth Muscle Cells
  264. Bildgebende Verfahren in Diagnostik und Verlaufskontrolle der pulmonalen arteriellen Hypertonie
  265. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy
  266. Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
  267. Diagnosis and Assessment of Pulmonary Arterial Hypertension
  268. Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension
  269. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review
  270. Inhaled iloprost for the treatment of pulmonary hypertension
  271. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension
  272. Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities
  273. A 55-year-old craftsman with dyspnea and clubbing: a case report
  274. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension
  275. Dana Point: Was ist neu in der Diagnostik der Pulmonalen Hypertonie?
  276. Magnetic Resonance–Derived 3-Dimensional Blood Flow Patterns in the Main Pulmonary Artery as a Marker of Pulmonary Hypertension and a Measure of Elevated Mean Pulmonary Arterial Pressure
  277. Oral and IntestinalCandidaColonization in Patients Undergoing Hematopoietic Stem‐Cell Transplantation
  278. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
  279. Prostacyclin therapies for the treatment of pulmonary arterial hypertension
  280. The Emerging Role of Magnetic Resonance Imaging in the Diagnosis and Management of Pulmonary Hypertension
  281. Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function
  282. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension
  283. Pulmonary Histoplasmosis in Three Austrian Travelers After a Journey to Mexico
  284. Highlights der Pulmonalen Hypertonie-Literatur
  285. Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes
  286. Delayed Processing of Blood Samples Influences Time to Positivity of Blood Cultures and Results of Gram Stain-Acridine Orange Leukocyte Cytospin Test
  287. Aspergillus oryzae Peritonitis in CAPD: Case Report and Review of the Literature
  288. Diagnostik und Therapie der chronischen pulmonalen Hypertonie
  289. Effect of Inhaled Iloprost during Off-Medication Time in Patients with Pulmonary Arterial Hypertension
  290. Diagnostik und Therapie der chronischen pulmonalen Hypertonie
  291. Derzeitige Empfehlungen zur Diagnostik und Therapie der pulmonalen Hypertonie
  292. Therapie der pulmonalarteriellen Hypertonie: Prostazyklin-Analoga
  293. Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension
  294. Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension
  295. Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension
  296. Stellenwert der Lyse bei akuter Lungenembolie
  297. Sildenafil treatment for portopulmonary hypertension
  298. Impact of TASK-1 in Human Pulmonary Artery Smooth Muscle Cells
  299. Pulmonale Hypertonie: Die Zukunft hat begonnen
  300. Mutations of the TGF-β type II receptorBMPR2 in pulmonary arterial hypertension
  301. Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension
  302. Diagnosis and treatment of pulmonary hypertonia
  303. Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension
  304. Enhanced Hypoxic Pulmonary Vasoconstriction in Families of Adults or Children With Idiopathic Pulmonary Arterial Hypertension
  305. Serotonin Transporter Gene Polymorphism in a Cohort of German Patients With Idiopathic Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
  306. Ketamine impairs excitability in superficial dorsal horn neurones by blocking sodium and voltage-gated potassium currents
  307. Ambrisentan Therapy for Pulmonary Arterial Hypertension
  308. Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar
  309. Medikament�se Therapie der pulmonalen Hypertonie
  310. Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension
  311. Novel case of dup(3q) syndrome due to a de novo interstitial duplication 3q24‐q26.31 with minimal overlap to the dup(3q) critical region
  312. Vasodilators in right heart failure - pro
  313. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertensionA randomized prospective study
  314. Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp
  315. Diagnosis and differential assessment of pulmonary arterial hypertension
  316. Prostanoid therapy for pulmonary arterial hypertension
  317. Prostacyclin and its analogues in the treatment of pulmonary hypertension
  318. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV‐related severe pulmonary hypertension
  319. Reversal of Nocturnal Periodic Breathing in Primary Pulmonary Hypertension After Lung Transplantation
  320. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia
  321. Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension
  322. Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure
  323. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension
  324. Primary pulmonary hypertension may be a heterogeneous disease with a second locus on chromosome 2q31
  325. Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension
  326. Increased neutrophil mediator release in patients with pulmonary hypertension – suppression by inhaled iloprost
  327. Pulmonaler Hochdruck
  328. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension
  329. Sildenafil zur Therapie der schweren pulmonalen Hypertonie und des beginnenden Rechtsherzversagens
  330. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
  331. Inhaled Iloprost for Severe Pulmonary Hypertension
  332. Peripheral airway obstruction in primary pulmonary hypertension
  333. Aerosolized Vasodilators in Pulmonary Hypertension
  334. Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension
  335. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: respondersversusnonresponders
  336. Nocturnal periodic breathing in primary pulmonary hypertension
  337. Outcome after Cardiopulmonary Resuscitation in Patients with Pulmonary Arterial Hypertension
  338. Cellular pathophysiology and therapy of pulmonary hypertension
  339. Recommendations for the Choice of Inhalatory Systems for Drug Prescription
  340. Physiologic basis for the treatment of pulmonary hypertension
  341. Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension
  342. Basic Electrical Properties ofIn situEndothelial Cells of Small Pulmonary Arteries during Postnatal Development
  343. Obstructive Sleep Apnoea and Cardiovascular Diseases - Hypothesis of Pathophysiological Interlinks
  344. Does the tuberous sclerosis complex include clivus chordoma? A case report
  345. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
  346. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy
  347. Diagnostik der akuten Lungenembolie - Empfehlungen der Deutsche Gesellschaft für Pneumologie -
  348. Prävalenz von Schlaganfall und transitorischer ischämischer Attacke (TIA) bei obstruktiver Schlaf-Apnoe: eine retrospektive Erhebung an 187 konsekutiven Patienten1
  349. Abnormal Pulmonary Artery Pressure Response in Asymptomatic Carriers of Primary Pulmonary Hypertension Gene
  350. Enhanced Release of Superoxide from Polymorphonuclear Neutrophils in Obstructive Sleep Apnea
  351. Inhalative Strategien zur Verbesserung der pulmonalen Hämodynamik und des Gasaustausches bei Sepsis und schwerer pulmonaler Hypertonie
  352. Behandlung der Pulmonal Arteriellen Hypertonie
  353. Screen–printed enzyme sensors for l-lysine determination
  354. Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial
  355. Inhaliertes Prostazyklin und Iloprost bei schwerer sekundärer pulmonaler Hypertonie durch Lungenfibrose1
  356. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
  357. Severe Microcirculatory Abnormalities Elicited byE. coliHemolysin in the Rabbit Ileum Mucosa
  358. Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis
  359. Physiologie und Pathophysiologie der pulmonalen Zirkulation
  360. Vasotrope Therapie und Beatmung bei pulmonaler Hypertonie
  361. Effect of bupivacaine on ATP-dependent potassium channels in rat cardiomyocytes
  362. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost
  363. Abnormalities of Gastric Mucosal Oxygenation in Septic Shock
  364. NO und alternative inhalative Therapieansätze bei pulmonaler Hypertonie
  365. Advantage of buffered solutions or automated capnometry in air-filled balloons for use in gastric tonometry
  366. Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension
  367. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome.
  368. ATP-Dependent Potassium Channel in Rat Cardiomyocytes Is Blocked by Lidocaine
  369. Temperature effects on ventilatory rate, heart rate, and preferred pedal rate during cycle ergometry
  370. Cardiac responses to the Valsalva manoeuvre in different body positions
  371. Thermoregulatory, cardiovascular, and muscular factors related to exercise after precooling
  372. Body temperature related factors diminishing the drive to exercise
  373. Pulmonary Hypertension